Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons
The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were signif...
Gespeichert in:
| Veröffentlicht in: | AIDS research and human retroviruses 1994, Vol.10, p.S105-S108 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S108 |
|---|---|
| container_issue | |
| container_start_page | S105 |
| container_title | AIDS research and human retroviruses |
| container_volume | 10 |
| creator | POWELL, M. F CLELAND, J. L EASTMAN, D. J LIM, A NEWMAN, M. J NUNBERG, J. H WEISSBURG, R. P VENNARI, J. C WRIN, T BERMAN, P. W |
| description | The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77760748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77760748</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-8ad65f5f1eaa702c53a8fd5882fe1bc96bd76a166393442efd6a3ab4bb4aa8823</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMoc05_gpAL8a6YJk2aXsrQbTAV8eO2nKTJiLTJbFJh_noLK16di-d5X17OCZrnFcszWRB-iuZEyiqjlFbn6CLGL0JIRSmfoVkpBaeSzpHfdN3gw854p106YPANXm8-sxz_uH6I2Jsh9dC6X0gueBwsfnrGvdGhU86DT3jXHnTY9yEZ53FOyd0x_fpGxwrQ2nmDR6JAheDjJTqz0EZzNd0F-nh8eF-us-3LarO832Z7ynjKJDSCW25zA1ASqjkDaRsuJbUmV7oSqikF5EKwihUFNbYRwEAVShUAo8UW6PbYOy77HkxMdeeiNm0L3oQh1mVZClIWchSvJ3FQnWnqfe866A_19KCR30wcoobW9uC1i_8aYwUdZ7E_BfFvXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77760748</pqid></control><display><type>article</type><title>Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>POWELL, M. F ; CLELAND, J. L ; EASTMAN, D. J ; LIM, A ; NEWMAN, M. J ; NUNBERG, J. H ; WEISSBURG, R. P ; VENNARI, J. C ; WRIN, T ; BERMAN, P. W</creator><creatorcontrib>POWELL, M. F ; CLELAND, J. L ; EASTMAN, D. J ; LIM, A ; NEWMAN, M. J ; NUNBERG, J. H ; WEISSBURG, R. P ; VENNARI, J. C ; WRIN, T ; BERMAN, P. W</creatorcontrib><description>The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.</description><identifier>ISSN: 0889-2229</identifier><identifier>EISSN: 1931-8405</identifier><identifier>PMID: 7865282</identifier><identifier>CODEN: ARHRE7</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject><![CDATA[Adjuvants, Immunologic - administration & dosage ; AIDS Vaccines - administration & dosage ; AIDS Vaccines - immunology ; AIDS/HIV ; Alum Compounds - administration & dosage ; Animals ; Biological and medical sciences ; HIV Antibodies - biosynthesis ; HIV Envelope Protein gp120 - administration & dosage ; HIV Envelope Protein gp120 - immunology ; HIV Seropositivity - immunology ; HIV-1 - immunology ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; In Vitro Techniques ; Medical sciences ; Neutralization Tests ; Papio ; Saponins - administration & dosage ; Saponins - immunology ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - immunology]]></subject><ispartof>AIDS research and human retroviruses, 1994, Vol.10, p.S105-S108</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,4010,4036,4037,23909,23910,25118</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3342588$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7865282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POWELL, M. F</creatorcontrib><creatorcontrib>CLELAND, J. L</creatorcontrib><creatorcontrib>EASTMAN, D. J</creatorcontrib><creatorcontrib>LIM, A</creatorcontrib><creatorcontrib>NEWMAN, M. J</creatorcontrib><creatorcontrib>NUNBERG, J. H</creatorcontrib><creatorcontrib>WEISSBURG, R. P</creatorcontrib><creatorcontrib>VENNARI, J. C</creatorcontrib><creatorcontrib>WRIN, T</creatorcontrib><creatorcontrib>BERMAN, P. W</creatorcontrib><title>Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons</title><title>AIDS research and human retroviruses</title><addtitle>AIDS Res Hum Retroviruses</addtitle><description>The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>AIDS Vaccines - administration & dosage</subject><subject>AIDS Vaccines - immunology</subject><subject>AIDS/HIV</subject><subject>Alum Compounds - administration & dosage</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>HIV Antibodies - biosynthesis</subject><subject>HIV Envelope Protein gp120 - administration & dosage</subject><subject>HIV Envelope Protein gp120 - immunology</subject><subject>HIV Seropositivity - immunology</subject><subject>HIV-1 - immunology</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Neutralization Tests</subject><subject>Papio</subject><subject>Saponins - administration & dosage</subject><subject>Saponins - immunology</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0889-2229</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF1LwzAUhoMoc05_gpAL8a6YJk2aXsrQbTAV8eO2nKTJiLTJbFJh_noLK16di-d5X17OCZrnFcszWRB-iuZEyiqjlFbn6CLGL0JIRSmfoVkpBaeSzpHfdN3gw854p106YPANXm8-sxz_uH6I2Jsh9dC6X0gueBwsfnrGvdGhU86DT3jXHnTY9yEZ53FOyd0x_fpGxwrQ2nmDR6JAheDjJTqz0EZzNd0F-nh8eF-us-3LarO832Z7ynjKJDSCW25zA1ASqjkDaRsuJbUmV7oSqikF5EKwihUFNbYRwEAVShUAo8UW6PbYOy77HkxMdeeiNm0L3oQh1mVZClIWchSvJ3FQnWnqfe866A_19KCR30wcoobW9uC1i_8aYwUdZ7E_BfFvXQ</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>POWELL, M. F</creator><creator>CLELAND, J. L</creator><creator>EASTMAN, D. J</creator><creator>LIM, A</creator><creator>NEWMAN, M. J</creator><creator>NUNBERG, J. H</creator><creator>WEISSBURG, R. P</creator><creator>VENNARI, J. C</creator><creator>WRIN, T</creator><creator>BERMAN, P. W</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1994</creationdate><title>Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons</title><author>POWELL, M. F ; CLELAND, J. L ; EASTMAN, D. J ; LIM, A ; NEWMAN, M. J ; NUNBERG, J. H ; WEISSBURG, R. P ; VENNARI, J. C ; WRIN, T ; BERMAN, P. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-8ad65f5f1eaa702c53a8fd5882fe1bc96bd76a166393442efd6a3ab4bb4aa8823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>AIDS Vaccines - administration & dosage</topic><topic>AIDS Vaccines - immunology</topic><topic>AIDS/HIV</topic><topic>Alum Compounds - administration & dosage</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>HIV Antibodies - biosynthesis</topic><topic>HIV Envelope Protein gp120 - administration & dosage</topic><topic>HIV Envelope Protein gp120 - immunology</topic><topic>HIV Seropositivity - immunology</topic><topic>HIV-1 - immunology</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Neutralization Tests</topic><topic>Papio</topic><topic>Saponins - administration & dosage</topic><topic>Saponins - immunology</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POWELL, M. F</creatorcontrib><creatorcontrib>CLELAND, J. L</creatorcontrib><creatorcontrib>EASTMAN, D. J</creatorcontrib><creatorcontrib>LIM, A</creatorcontrib><creatorcontrib>NEWMAN, M. J</creatorcontrib><creatorcontrib>NUNBERG, J. H</creatorcontrib><creatorcontrib>WEISSBURG, R. P</creatorcontrib><creatorcontrib>VENNARI, J. C</creatorcontrib><creatorcontrib>WRIN, T</creatorcontrib><creatorcontrib>BERMAN, P. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POWELL, M. F</au><au>CLELAND, J. L</au><au>EASTMAN, D. J</au><au>LIM, A</au><au>NEWMAN, M. J</au><au>NUNBERG, J. H</au><au>WEISSBURG, R. P</au><au>VENNARI, J. C</au><au>WRIN, T</au><au>BERMAN, P. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons</atitle><jtitle>AIDS research and human retroviruses</jtitle><addtitle>AIDS Res Hum Retroviruses</addtitle><date>1994</date><risdate>1994</risdate><volume>10</volume><spage>S105</spage><epage>S108</epage><pages>S105-S108</pages><issn>0889-2229</issn><eissn>1931-8405</eissn><coden>ARHRE7</coden><abstract>The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>7865282</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-2229 |
| ispartof | AIDS research and human retroviruses, 1994, Vol.10, p.S105-S108 |
| issn | 0889-2229 1931-8405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77760748 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Adjuvants, Immunologic - administration & dosage AIDS Vaccines - administration & dosage AIDS Vaccines - immunology AIDS/HIV Alum Compounds - administration & dosage Animals Biological and medical sciences HIV Antibodies - biosynthesis HIV Envelope Protein gp120 - administration & dosage HIV Envelope Protein gp120 - immunology HIV Seropositivity - immunology HIV-1 - immunology Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology In Vitro Techniques Medical sciences Neutralization Tests Papio Saponins - administration & dosage Saponins - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology |
| title | Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T22%3A10%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20HIV-1%20virus%20neutralization%20of%20MN%20recombinant%20glycoprotein%20120/HIV-1%20QS21%20vaccine%20in%20baboons&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=POWELL,%20M.%20F&rft.date=1994&rft.volume=10&rft.spage=S105&rft.epage=S108&rft.pages=S105-S108&rft.issn=0889-2229&rft.eissn=1931-8405&rft.coden=ARHRE7&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E77760748%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77760748&rft_id=info:pmid/7865282&rfr_iscdi=true |